Abstract
Preclinical evidence points to disturbances in neural networks in psychosis involving interrelations between dopaminergic-, GABAergic- and glutamatergic neurotransmitter systems. In support, we have previously shown that aberrant interrelations between these neurotransmitters, in contrast to individual transmitter systems, can separate antipsychotic-naïve first-episode psychotic patients (AN-FEP) from healthy controls (HC). Here, we characterized neurotransmitter interrelations, examined their association with treatment response, and explored the effect of treatment on the interrelations.
Sixty participants (29 AN-FEP and 31 HC) underwent dynamic [18F]-DOPA PET with arterial blood sampling using a four-parameter model to measure dopamine synthesis (DS) (k3) in nucleus accumbens (NAcc) and magnetic resonance spectroscopy (MRS) to estimate levels of glutamate (Glu) in anterior cingulate cortex (ACC) and thalamus, and gamma-aminobutyric-acid (GABA) in ACC. A subgroup of the patients was re-scanned after six weeks antipsychotic monotherapy with aripiprazole. Psychopathology was assessed at both visits. Multiple linear regression models and linear mixed models were used to analyze data.
We found a negative association between k3 (dependent variable) and GABA in HC (β=-0.15, p=0.03) and a positive association in patients (β=0.15, p=0.04). The aberrant relationship between k3 and GABA was driven by the group-GABA interaction (p=0.002) and related to treatment response (p=0.02). No significant group interactions were found for the interrelations between k3 and Glu, but a positive association was found between k3 and Glu in thalamus (p=0.04) in both groups and the association decreased after treatment in AN-FEP (p=0.01).
The data show that DS in NAcc and GABA levels in ACC are inversely interrelated in AN-FEP, and that the degree of abnormality predicts treatment effect. Moreover, antipsychotic treatment alters the relationship between dopaminergic activity in NAcc and Glu levels in thalamus. The findings suggest that combined instead of single neurotransmitter disturbances should be considered when novel therapeutics are developed for schizophrenia.
Competing Interest Statement
Dr. Glenthoej has been the leader of a Lundbeck Foundation Centre of Excellence for Clinical Intervention and Neuropsychiatric Schizophrenia Research (CINS) (January 2009 to December 2021), which was partially financed by an independent grant from the Lundbeck Foundation based on international review and partially financed by the Mental Health Services in the Capital Region of Denmark, the University of Copenhagen, and other foundations. All grants are the property of the Mental Health Services in the Capital Region of Denmark and administrated by them. She has no other conflicts to disclose. Dr. Bojesen received lecture fees from Lundbeck Pharma A/S. Dr. Ebdrup BE is part of the Advisory Board of Boehringer Ingelheim, Lundbeck Pharma A/S; and has received lecture fees from Boehringer Ingelheim, Otsuka Pharma Scandinavia AB, and Lundbeck Pharma A/S. The rest of the authors have no conflicts of interest to disclose.
Clinical Protocols
https://www.clinicaltrials.gov/study/NCT02339844
Funding Statement
This study was funded by an independent grant from the Lundbeck Foundation (R155-2013-16337) to the Lundbeck Foundation Centre of Excellence for Clinical Intervention and Neuropsychiatric Schizophrenia Research (CINS) (Glenthoej), grants from the Woerzner and Gerhard Linds Foundations and support from the Mental Health Services, Capital Region of Denmark (Glenthoej and Ebdrup). PhD grants and a post doc grant were obtained from the Mental Health Services in the Capital Region of Denmark (Sigvard), the Faculty of Health and Medical Sciences, University of Copenhagen (Bojesen), the research Fund 2022 in the Capital Region of Denmark (Bojesen), and an independent grant from the Lundbeck Foundation (R403-2022-1361). The funding sources had no role in the design or conduction of the study design, nor in the collection, analyses, and interpretation of data, or in the writing, review approval and submission of the manuscript for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Committee on Biomedical Research Ethics in the capital region of Denmark gave ethical approval for this work (H-3-2013-149)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
First authors can be contacted about availability of the data.
